Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has a higher price-to-earnings ratio of 30.38x compared to its average ratio. AUPH has 36-month beta value of 1.24. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AUPH is 119.37M, and currently, short sellers hold a 8.82% ratio of that float. The average trading volume of AUPH on July 10, 2025 was 1.35M shares.
AUPH) stock’s latest price update
The stock of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has increased by 10.54% when compared to last closing price of $7.59. Despite this, the company has experienced a 12.17% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-07-07 that I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year to $60 million and management reaffirm FY2025 guidance. The company has a strong balance sheet, a free cash flow turnaround, and projected profit growth to $0.59/share in FY2025 to support a positive investment outlook.
AUPH’s Market Performance
Aurinia Pharmaceuticals Inc (AUPH) has seen a 12.17% rise in stock performance for the week, with a 2.44% gain in the past month and a 10.54% surge in the past quarter. The volatility ratio for the week is 4.41%, and the volatility levels for the past 30 days are at 4.10% for AUPH. The simple moving average for the past 20 days is 4.84% for AUPH’s stock, with a 4.31% simple moving average for the past 200 days.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at 4.11% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.37% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Keenan Greg, who sale 8,305 shares at the price of $8.23 back on Mar 07 ’25. After this action, Keenan Greg now owns 153,484 shares of Aurinia Pharmaceuticals Inc, valued at $68,350 using the latest closing price.
Greenleaf Peter, the Chief Executive Officer of Aurinia Pharmaceuticals Inc, sale 195,593 shares at $8.00 during a trade that took place back on Mar 03 ’25, which means that Greenleaf Peter is holding 1,953,892 shares at $1,564,744 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.88 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at 0.16. The total capital return value is set at 0.07. Equity return is now at value 11.23, with 7.80 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 0.83. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 12.55.
Currently, EBITDA for the company is 31.73 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 4.63. The receivables turnover for the company is 6.13for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.93.
Conclusion
To put it simply, Aurinia Pharmaceuticals Inc (AUPH) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
